Skip to content
Head to head

Dr. Reddy's Laboratories vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: RDY · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

RDY +7.4%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
RDYTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price14.8921.77
Change today+0.40%+1.68%
1-year return+7.9%+57.5%
Market cap$12.41B$69.76B
52-week range11.28 – 15.5613.92 – 22.07
Valuation
P/E (TTM)41.36311.00
P/E percentile, own 5-yr range99th100th
P/B3.001.50
Dividend yield0.56%1.44%
Profitability & growth
EPS (TTM)0.55-0.30
Net profit (TTM)$459.35M$-970.94M
Revenue (TTM)$329.84B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-1.5%+6.7%
Gross margin49.5%65.8%
Operating margin9.5%14.3%
Net margin8.5%0.9%
Free cash flow (TTM)$4.74B$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership63.7%51.3%
Insider activity (12mo)0 buy / 1 sell19 buy / 31 sell
Short interest (% of float)3.0%0.1%
Analyst consensus67% buy / 33% hold (3)100% buy (1)
Analyst price target$14 (-3%)$50 (+132%)
StockVane view
StockVane Quant RatingC (48)C (90)
Company
Employees27,52747,029
Founded19841781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.